ArticleScience (New York, N.Y.)2026
Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Covalent tumor anchoring spatially orchestrates antitumor immunity.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Grayson E Rodriguez *Immunology Program, Stanford University, Stanford, CA, USA.ORCID 0009-0002-7386-2050
Yang Zhao *Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-6596-499X
Yoko NishigaDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Frank PeprahDepartment of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.ORCID 0009-0004-6213-487X
Jiao ShenDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9267-0738
Gita C AbhiramanImmunology Program, Stanford University, Stanford, CA, USA.ORCID 0000-0002-0546-4133
Masato OgishiDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-2421-7389
Chenyu ZhangDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-3199-9422
Justin SacoDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0001-6466-5245
Deepa WaghrayDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Mamatha SerasanambatiDepartment of Surgery, Division of Surgical Oncology, Stanford School of Medicine, Stanford University Medical Center, Stanford, CA, USA.ORCID 0000-0003-1470-305X
Leonel TorresInstitute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.
Brandon W SimoneCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.ORCID 0000-0003-3907-3015
Leon SuDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-7654-9997
Steven C WilsonDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-7382-3388
Aerin YangDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-8704-0288
Qinli SunDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-1220-3388
Lora PictonDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-0482-5187
Robert A SaxtonDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-9777-8270
Vidit BhandarkarKoch Institute at MIT, Cambridge, MA, USA.ORCID 0000-0002-6526-4360
Madeline J LeeImmunology Program, Stanford University, Stanford, CA, USA.ORCID 0000-0001-5039-6806
Elizabeth AndrewsDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-2265-2486
Hua JiangDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0009-0006-9506-119X
Matthias ObenausDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-5090-9162
Michelle YenDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Tavus AtajanovaDepartment of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
Catherine A BlishDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-6946-7627
Stefani SprangerKoch Institute at MIT, Cambridge, MA, USA.ORCID 0000-0003-3257-4546
E John WherryInstitute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.ORCID 0000-0003-0477-1956
Amanda KiraneDepartment of Surgery, Division of Surgical Oncology, Stanford School of Medicine, Stanford University Medical Center, Stanford, CA, USA.ORCID 0000-0003-3489-1182
Antoni RibasDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.ORCID 0000-0003-3669-8458
David H RauletDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-1257-8649
Anusha KalbasiDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-8692-1457
Stephanie K DouganDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-2263-363X
Michael DouganDepartment of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-9266-2009
Julien SageDepartment of Pediatrics, Stanford University, Stanford, CA, USA.ORCID 0000-0002-8928-9968
K Christopher GarciaDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-9273-0278
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007365 · NIGMS · STANFORD UNIVERSITY · PI CHUA, KATRIN F · 1985 to 2021
$33.8MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MUCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3MStructure-based engineering of immune cytokine signalingR01AI051321 · NIAID · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2002 to 2026
$5.6MMolecular Pathways Regulating Tissue-resident Memory T cells in the GutR01AI169188 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Michael Lawrence Dougan · 2022 to 2026
$3.0MMechanisms underlying combination therapy mobilizing NK cellsR01CA270790 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI DAVID H RAULET · 2022 to 2026
$2.3MCDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humansR01AI158488 · NIAID · DANA-FARBER CANCER INST · PI DOUGAN, STEPHANIE · 2021 to 2025
$2.2MUnderstanding the induction of T cell dysfunction in the context of lung cancerR37CA273819 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Stefani Spranger · 2023 to 2026
$1.9MSynthetic IL9R signaling to rewire T cells for adoptive cell therapy of cancerR37CA273074 · NCI · STANFORD UNIVERSITY · PI Anusha Kalbasi · 2022 to 2026
$1.8MGenetic and immunological dissection of coinhibitory crosstalks between human T cells and cancer cellsK00CA274708 · NCI · STANFORD UNIVERSITY · PI Masato Ogishi · 2024 to 2026
$297kHoward Hughes Medical InstituteNCI NIH HHS K00 CA274708NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA270790NCI NIH HHS R35 CA197633NCI NIH HHS R37 CA273074NCI NIH HHS R37 CA273819NCI NIH HHS T32 CA009120NIAID NIH HHS R01 AI051321NIAID NIH HHS R01 AI158488NIAID NIH HHS R01 AI169188NIGMS NIH HHS T32 GM007365
Abstract
Cytokines dimerize two receptor chains to activate Janus kinases and signal transducer and activator of transcription (STAT) transcription factors that regulate immune cells, but they have therapeutic liabilities. We engineered "Trikines" to compel
Indexed as
CytokinesImmunotherapyInterleukin-10Interleukin-2Signal TransductionSTAT3 Transcription FactorSTAT5 Transcription FactorAnimalsCell DifferentiationCell Line, TumorHumansLung NeoplasmsMicePhosphorylationProtein EngineeringProtein MultimerizationCytokinesInterleukin-10Interleukin-2Receptors, InterleukinSTAT3 Transcription FactorSTAT5 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.